Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136975> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4324136975 endingPage "138" @default.
- W4324136975 startingPage "138" @default.
- W4324136975 abstract "138 Background: Prostate cancer (PCa) is the most common non-skin cancer affecting American men. Two common NHTs used to treat PCa are enzalutamide and abiraterone. Due to the different mechanisms of these two NHTs, we hypothesized that the concomitant medications prescribed might be related to therapy-related adverse effects. The purpose of this study was to examine whether changes in concomitant medications depended on the NHT prescribed. Methods: Medicare patients with a prescription of either enzalutamide or abiraterone in the Surveillance, Epidemiology, and End Results (SEER)–Medicare database diagnosed with prostate cancer from January 01, 2004 to December 31, 2015 were included. Medications were classified by Lexicomp’s pharmacologic category. Only oral prescriptions were included. McNemar’s test was used to compare the drug use prevalence of each category prior to and after initiation of NHT. Generalized logistic regression was used to evaluate whether changes in prescription drug class during the 6 months post-NHT initiation periods depended on the type of NHT. Results: Among the 1067 patients included, 354 were prescribed enzalutamide and 713 were prescribed abiraterone. We found statistically significant interactions between NHT (enzalutamide vs. abiraterone) and period (post vs. preinitiation NHT). Patients prescribed enzalutamide were more likely to discontinue prescriptions for steroids (p<0.01) as expected. The odds of fluoroquinolones, non-steroidal anti-inflammatory drugs (NSAIDs), and loop diuretics prescriptions were similar pre-NHT initiation for both enzalutamide and abiraterone patients; however, patients treated with enzalutamide were significantly less likely than abiraterone patients to have post-NHT initiation prescriptions for fluoroquinolones (Odds ratio (OR) 0.69 p=0.01) or loop diuretics (OR: 0.57 p<0.01). Conclusions: To our knowledge, this is the first population-based study to describe concurrent medication prescribing before and after NHT. Further studies are warranted to better understand the underlying reasons for the observed patterns." @default.
- W4324136975 created "2023-03-15" @default.
- W4324136975 creator A5010241768 @default.
- W4324136975 creator A5010670331 @default.
- W4324136975 creator A5013964649 @default.
- W4324136975 creator A5024328077 @default.
- W4324136975 creator A5069632888 @default.
- W4324136975 creator A5076724943 @default.
- W4324136975 creator A5078719816 @default.
- W4324136975 date "2023-02-20" @default.
- W4324136975 modified "2023-09-30" @default.
- W4324136975 title "Differences in concomitant medication prescribing before and after novel hormonal therapy (NHT) in men with prostate cancer: A population-based study." @default.
- W4324136975 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.138" @default.
- W4324136975 hasPublicationYear "2023" @default.
- W4324136975 type Work @default.
- W4324136975 citedByCount "0" @default.
- W4324136975 crossrefType "journal-article" @default.
- W4324136975 hasAuthorship W4324136975A5010241768 @default.
- W4324136975 hasAuthorship W4324136975A5010670331 @default.
- W4324136975 hasAuthorship W4324136975A5013964649 @default.
- W4324136975 hasAuthorship W4324136975A5024328077 @default.
- W4324136975 hasAuthorship W4324136975A5069632888 @default.
- W4324136975 hasAuthorship W4324136975A5076724943 @default.
- W4324136975 hasAuthorship W4324136975A5078719816 @default.
- W4324136975 hasConcept C121608353 @default.
- W4324136975 hasConcept C126322002 @default.
- W4324136975 hasConcept C143998085 @default.
- W4324136975 hasConcept C2776421732 @default.
- W4324136975 hasConcept C2776551883 @default.
- W4324136975 hasConcept C2777899217 @default.
- W4324136975 hasConcept C2779384505 @default.
- W4324136975 hasConcept C2780192828 @default.
- W4324136975 hasConcept C2908647359 @default.
- W4324136975 hasConcept C61367390 @default.
- W4324136975 hasConcept C71924100 @default.
- W4324136975 hasConcept C99454951 @default.
- W4324136975 hasConceptScore W4324136975C121608353 @default.
- W4324136975 hasConceptScore W4324136975C126322002 @default.
- W4324136975 hasConceptScore W4324136975C143998085 @default.
- W4324136975 hasConceptScore W4324136975C2776421732 @default.
- W4324136975 hasConceptScore W4324136975C2776551883 @default.
- W4324136975 hasConceptScore W4324136975C2777899217 @default.
- W4324136975 hasConceptScore W4324136975C2779384505 @default.
- W4324136975 hasConceptScore W4324136975C2780192828 @default.
- W4324136975 hasConceptScore W4324136975C2908647359 @default.
- W4324136975 hasConceptScore W4324136975C61367390 @default.
- W4324136975 hasConceptScore W4324136975C71924100 @default.
- W4324136975 hasConceptScore W4324136975C99454951 @default.
- W4324136975 hasFunder F4320332161 @default.
- W4324136975 hasIssue "6_suppl" @default.
- W4324136975 hasLocation W43241369751 @default.
- W4324136975 hasOpenAccess W4324136975 @default.
- W4324136975 hasPrimaryLocation W43241369751 @default.
- W4324136975 hasRelatedWork W1652439388 @default.
- W4324136975 hasRelatedWork W2015876133 @default.
- W4324136975 hasRelatedWork W2021751111 @default.
- W4324136975 hasRelatedWork W2162738516 @default.
- W4324136975 hasRelatedWork W2762424895 @default.
- W4324136975 hasRelatedWork W2768013934 @default.
- W4324136975 hasRelatedWork W2768688864 @default.
- W4324136975 hasRelatedWork W2911632751 @default.
- W4324136975 hasRelatedWork W2996229517 @default.
- W4324136975 hasRelatedWork W3014214351 @default.
- W4324136975 hasVolume "41" @default.
- W4324136975 isParatext "false" @default.
- W4324136975 isRetracted "false" @default.
- W4324136975 workType "article" @default.